Abbisko starts Phase 2 test of ABSK043 plus AstraZeneca's osimertinib in NSCLC
The China-based trial pairs Abbisko's EGFR inhibitor with the world's leading osimertinib-based regimen in a lung cancer field crowded with 21 direct EGFR-targeted comparators.
Executive Summary
- Abbisko Therapeutics registered a Phase 2 study combining its EGFR inhibitor with AstraZeneca's osimertinib in non-small cell lung cancer, structured as a dose-escalation and expansion design that starts by testing tolerability before efficacy.
- This is the fourth active Abbisko trial built around the same drug, each pairing it with a different combination partner, pointing to a company betting on combination potentiation of EGFR blockade rather than a single monotherapy path.
- The trial enters a lung cancer field where EGFR-targeted therapy is already validated and densely populated, so the informative question is whether adding a second EGFR-directed small molecule to osimertinib overcomes resistance mechanisms that current combinations do not fully address.
- No efficacy or safety data exist yet because the trial has not started enrolling, so its near-term value is informational: it signals sponsor intent and combination strategy rather than a readable clinical result.
The registration
Abbisko Therapeutics Co, Ltd filed a new Phase 2 study, NCT07710612, testing ABSK043 combined with osimertinib in patients with locally advanced or metastatic non-small cell lung cancer. The trial is not yet recruiting, plans to start in August 2026, and targets 72 patients across sites in China. It carries a dose-escalation and expansion design in an open-label, single-arm structure, with a primary completion date set for December 2029. NCT07710612A Phase 2 Study of ABSK043 Combined With OsimertinibNCT07710612
What the endpoint tests
The escalation portion's primary endpoints are the incidence of dose-limiting toxicity, adverse events of special interest, and serious adverse events measured through the end of the first 21-day cycle and beyond, a tolerability read rather than an efficacy one. The expansion portion adds progression-free survival at 12 months as a primary measure, alongside secondary endpoints spanning objective response rate, disease control rate, duration of response, and overall survival tracked out to five to seven years. Eligible patients must have documented EGFR alteration and PD-L1 expression, and the escalation cohort requires prior progression on a third-generation EGFR-TKI, positioning the combination as a next-line option after osimertinib resistance develops. NCT07710612A Phase 2 Study of ABSK043 Combined With OsimertinibNCT07710612
A pattern, not a one-off
ABSK043 already anchors three other active Abbisko trials: one combining it with ABSK061 across gastric, urothelial, and lung cancers, one pairing it with the KRAS G12C inhibitor glecirasib in NSCLC, and one combining it with firmonertinib, another EGFR-targeted agent, also in NSCLC. Abbisko has completed 12 of its 12 closed trials across its broader pipeline, with no terminations on record. Adding osimertinib as a fourth combination partner extends a deliberate strategy of testing ABSK043 alongside multiple targeted agents rather than developing it alone. NCT07710612A Phase 2 Study of ABSK043 Combined With OsimertinibNCT07710612
The competitive field
EGFR-targeted therapy in NSCLC is a mature, crowded area: 21 trials qualify as direct comparators sharing the EGFR target and small-molecule or antibody modality, including AstraZeneca's own osimertinib in a Phase 4 setting, Taiho Oncology's zipalertinib and AbbVie's telisotuzumab adizutecan in Phase 3, and several Chinese-sponsored EGFR-TKI and antibody-drug-conjugate programs such as Sichuan Baili's BL-B01D1 and Suzhou Suncadia's SHR-A2009. EGFR remains one of the most heavily pursued targets in NSCLC by trial count, alongside PD-1 and PD-L1. Against that backdrop, a combination that overcomes osimertinib resistance without adding toxicity beyond what dual EGFR blockade typically produces would be the signal that distinguishes this program from the rest of the field.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.